Replies to post #20922 on FROGGER'S HIDEOUT

[OCKHAM'S RAZOR]

TSOI 1.3M VOLUME 10 DAY AVG_1.3M .0071 +36.54%

DR. ICHIM FROM CELZ IS ON WITH TSOI

Therapeutic Solutions International Launches Multi-Protocol Cancer Immunotherapy Clinical Trial with Pan Am Cancer Treatment

Company Aims to Leverage Transfer Factor Pulsed Autologous Dendritic Cells on StemVacs Platform with Patented Augmenter of Cancer Immunotherapy NanoStilbene

Oceanside, CA -- May 01, 2018 -- InvestorsHub NewsWire -- Therapeutic Solutions International, Inc., (OTC Markets: TSOI) announced today signing of an agreement with the Pan Am Cancer Treatment Center covering production and clinical implementation of its patent pending StemVacs Platform in combination with our Patented immunological adjuvant NanoStilbene.

StemVacs is generated using dendritic cell progenitors isolated from patients, which are activated by a proprietary process which has previously been demonstrated to endow dendritic cells with the ability to produce "natural cytokines", which kill cancer cells. NanoStilbene, a nanoparticle formulation of pterostilbene is covered for use in cancer immunotherapy under the Company's issued U.S. Patent No.: 9,682,047. Pterostilbene is the active ingredient in the Company's patented ProJuvenol product.

StemVacs is also subject of a filed Investigational New Drug Application (IND #17448) with the U.S. FDA. The IND seeks to establish safety and immune response of cancer, targeting a new personalized dendritic cell vaccine.

The Pan Am Cancer Treatment Center is a premier clinical research and treatment facility located in Tijuana, Mexico, which has been offering dendritic cell therapy for treatment of cancer patients. The current collaboration will leverage existing cellular therapy manufacturing expertise to develop and clinically apply, transfer factor pulsed autologous dendritic cells on the StemVacs Platform to patients.

"Having previously treated 10 patients with StemVacs in a proof-of-concept trial in collaboration with the Pan Am Cancer Treatment Center, we are very excited to expand the number of patients receiving this investigational immunotherapeutic approach" said Timothy Dixon, President and Chief Executive Officer of TSOI. "Under Compassionate Use and Right to Try, we are able to offer this fee-for-service treatment not available anywhere else in the world and very pleased to do so and even more pleased that every patient treated will also be adding NanoStilbene to their personalized treatment protocol"

"We are eager to offer this multi-protocol cancer immunotherapy to our patients, many of which who do not have any other treatment options available," said Dr. Javier Lopez, Chief Executive Officer of the Pan American Cancer Treatment Center. "By working with internationally renowned experts, such as the Scientific Advisory Board of Therapeutic Solutions International, we will strive to provide the most advanced immunotherapy for our patients."

"StemVacs is an immuno-oncology cellular therapy that programs the immune system to selectively attack malignant cells expressing the protein CTCFL, which acts as a "Master Orchestrator" of numerous genes needed for cancer to be cancer. Specifically, CTCFL is known to induce genes associated with cancer spreading, cancer mutating, and cancer becoming resistant to conventional therapies" said Thomas E Ichim, Ph.D., Board Member of TSOI. "Recent studies have found an association between CTCFL and cancer stem cells, suggesting the possibility that StemVacs actively destroys the "root" of the tumor, thus potentially increasing the probability of efficacy. I am particularly excited about the combination with NanoStilbene, whose active ingredient has previously been reported to possess activity against breast cancer and prostate cancer, the two cancers that we are actively treating."

About Therapeutic Solutions International, Inc.
The Company's corporate website is www.therapeuticsolutionsint.com. Our new products can be viewed on www.projuvenol.com and products can be ordered at www.youcanordernow.com.
_____________________________________________________________________


Therapeutic Solutions International, Inc. Recruits Top Doctor of San Diego to Scientific Advisory Board
1:19 pm ET February 27, 2018 (PR Newswire) Print
Therapeutics Solutions International, Inc., (OTC Markets: TSOI) announced today that James Drew Veltmeyer, M.D., has been appointed to the Company's Scientific Advisory Board.

Dr. James Veltmeyer, MD is a board certified family physician in La Mesa, California. A graduate of UC San Diego and the Ross University School of Medicine, he completed his residency through the UC San Francisco system where he became Chief of Family Medicine Residency, overseeing 36 doctors. Dr. Veltmeyer, a member of the San Diego Critical Care Medical Group, has been elected for four years (2012, 2014, 2016, and 2017) by his colleagues in the San Diego County Medical Society as a "Physician of Exceptional Excellence," the most prestigious honor awarded to a "Top Doctor" in San Diego County. He is among a select group of San Diego physicians who was chosen four of the last fifteen years and he consistently ranks in the top 1% to 2% for patient satisfaction. He is currently the Chief of the Department of Family Medicine at Sharp Grossmont Hospital where he provides senior leadership to over 200 doctors.

"It is our great pleasure to welcome Dr. James Veltmeyer to our Scientific Advisory Board. Dr. Veltmeyer in coming to this country at age eleven after suffering homelessness and hardship in his South American country of birth, Dr. Veltmeyer has achieved phenomenal success because he had an opportunity to come to the United States and enter our educational system where he pursued the field of medicine. We are deeply honored to have Dr. Veltmeyer on our distinguished scientific team," said Timothy Dixon, President and CEO.

"I am enthusiastic to work besides the team assembled by Mr. Dixon in advancing the commercialization of the patented pterostilbene-based immunotherapeutic products for treatment of cancer and other medical conditions," said Dr. Veltmeyer.

"Dr. Veltmeyer possesses unparalleled insight in the practice of medicine. Combined with his unique curiosity and problem solving mindset, we are very eager to begin our collaborations with Dr. Veltmeyer, which we believe will translate into new treatments for patients," said Dr. Thomas Ichim, Board Member of TSOI and CEO of Emvolio, Inc.

About Therapeutic Solutions International, Inc. Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. Immune modulation refers to the ability to upregulate (make more active) or downregulate (make less active) one's immune system. The Company's corporate website is www.therapeuticsolutionsint.com.